Opium (Opioid) Addiction - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 80 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Opium (Opioid) Addiction - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Opium (Opioid) Addiction - Pipeline Review, H2 2014', provides an overview of the Opium (Opioid) Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Opium (Opioid) Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Opium (Opioid) Addiction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Opium (Opioid) Addiction Overview 8
Therapeutics Development 9
Pipeline Products for Opium (Opioid) Addiction - Overview 9
Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis 10
Opium (Opioid) Addiction - Therapeutics under Development by Companies 11
Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes 13
Opium (Opioid) Addiction - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Opium (Opioid) Addiction - Products under Development by Companies 16
Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes 17
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 18
Alkermes Plc 18
Nanotherapeutics, Inc. 19
Acura Pharmaceuticals, Inc. 20
Catalyst Pharmaceutical Partners, Inc. 21
INSYS Therapeutics, Inc. 22
Camurus AB 23
Omeros Corporation 24
D&A Pharma SAS 25
Reckitt Benckiser Pharmaceutical, Inc. 26
AllTranz, Inc. 27
Relmada Therapeutics, Inc. 28
Celtic Pharmaceutical Holdings L.P. 29
Foresee Pharmaceuticals, LLC 30
Opium (Opioid) Addiction - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
TA-CD - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
buprenorphine hydrochloride - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
RBP-6300 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cannabidiol - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
OMS-405 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
MAL - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
samidorphan - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CPP-115 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
OMS-527 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
buprenorphine hydrochloride ER - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Vaccine for Opium Addiction - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cannabidiol - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
FP-004 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
methadone IR - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
buprenorphine hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
naltrexone - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Opium (Opioid) Addiction - Recent Pipeline Updates 64
Opium (Opioid) Addiction - Dormant Projects 68
Opium (Opioid) Addiction - Discontinued Products 69
Opium (Opioid) Addiction - Product Development Milestones 70
Featured News & Press Releases 70
Aug 18, 2014: MediciNova Announces Positive Interim Results of Phase 2a Study of MN-166 (ibudilast) in Opioid Dependence 70
Jan 15, 2014: Collegium Pharmaceutical Announces Positive Topline Results of Human Abuse Potential Study Evaluating Intranasal Administration of Crushed Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Product 71
Dec 05, 2013: Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201 72
Jul 29, 2013: Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614 73
Jul 18, 2013: Collegium Pharmaceutical Announces Notice of Allowance for U.S. Patent Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product 74
Mar 20, 2013: MediciNova Presents Phase Ib/IIa Study Data Of Ibudilast At American Academy Of Neurology Annual Meeting 74
Feb 12, 2013: Collegium Pharma Announces Notice Of Allowance For US Patent Covering Oxycodone DETERx Extended-release Opioid Product 76
Jan 03, 2013: MediciNova Provides Development Update On MN-166 77
Nov 20, 2012: MediciNova Initiates Phase IIa Trial Of MN-166 In Opioid Abusers 77
Nov 08, 2012: Catalyst Pharma Announces Top-Line Results Of CPP-109 Phase IIb Trial For Cocaine Addiction 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

List of Tables
Number of Products under Development for Opium (Opioid) Addiction, H2 2014 9
Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2014 18
Opium (Opioid) Addiction - Pipeline by Nanotherapeutics, Inc., H2 2014 19
Opium (Opioid) Addiction - Pipeline by Acura Pharmaceuticals, Inc., H2 2014 20
Opium (Opioid) Addiction - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2014 21
Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2014 22
Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2014 23
Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H2 2014 24
Opium (Opioid) Addiction - Pipeline by D&A Pharma SAS, H2 2014 25
Opium (Opioid) Addiction - Pipeline by Reckitt Benckiser Pharmaceutical, Inc., H2 2014 26
Opium (Opioid) Addiction - Pipeline by AllTranz, Inc., H2 2014 27
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2014 28
Opium (Opioid) Addiction - Pipeline by Celtic Pharmaceutical Holdings L.P., H2 2014 29
Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Assessment by Combination Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 38
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
Opium (Opioid) Addiction Therapeutics - Recent Pipeline Updates, H2 2014 64
Opium (Opioid) Addiction - Dormant Projects, H2 2014 68
Opium (Opioid) Addiction - Discontinued Products, H2 2014 69